227
Views
0
CrossRef citations to date
0
Altmetric
Commentary

The Gpi Anchor Pathway: A Promising Antifungal Target?

&
Pages 1387-1391 | Received 06 Jun 2016, Accepted 15 Jun 2016, Published online: 11 Aug 2016
 

Financial & competing interests disclosure

M Mutz is a founder and shareholder of Amplyx Pharmaceuticals. T Roemer is an employee of Merck & Co. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

M Mutz is a founder and shareholder of Amplyx Pharmaceuticals. T Roemer is an employee of Merck & Co. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.